| Symbol | PRPO |
|---|---|
| Name | PRECIPIO, INC. |
| Sector | INDUSTRIALS |
| Region | North America |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Address | 4 SCIENCE PARK, NEW HAVEN, Connecticut, 06511, United States |
| Telephone | +1 203 787-7888 |
| Fax | — |
| — | |
| Website | https://www.precipiodx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001043961 |
| Description | Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provide new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. Additional info from NASDAQ: |
Director Valauri Christina Rizopoulos 🟢 acquired 108 shares of Precipio, Inc. (PRPO) at $25.24 Transaction Date: Jul 15, 2026 | Filing ID: 084267
Read moreDirector Cohen David Seth 🟢 acquired 520 shares of Precipio, Inc. (PRPO) at $25.24 Transaction Date: Jul 15, 2026 | Filing ID: 084263
Read morePrecipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Read more